
Global Gastrointestinal Stromal Tumor Drug Market by Size, by Type, by Application, by Region, History and Forecast 2020-2031
Description
Summary
According to APO Research, The global Gastrointestinal Stromal Tumor Drug market is projected to grow from US$ million in 2025 to US$ million by 2031, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.
The US & Canada market for Gastrointestinal Stromal Tumor Drug is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for Gastrointestinal Stromal Tumor Drug is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The China market for Gastrointestinal Stromal Tumor Drug is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Europe market for Gastrointestinal Stromal Tumor Drug is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global manufacturers of Gastrointestinal Stromal Tumor Drug include China Biopharmaceuticals, Zai Lab, CSPC Pharmaceuticals, Novartis, Mylan Pharms Inc., Kelun Pharmaceuticals, CStone Pharmaceuticals, Hansoh Pharmaceuticals and Vannsh Life Sciences, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
This report presents an overview of global market for Gastrointestinal Stromal Tumor Drug, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2020-2024, estimates for 2025, and projections of CAGR through 2031.
This report researches the key producers of Gastrointestinal Stromal Tumor Drug, also provides the sales of main regions and countries. Of the upcoming market potential for Gastrointestinal Stromal Tumor Drug, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Gastrointestinal Stromal Tumor Drug sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Gastrointestinal Stromal Tumor Drug market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for Gastrointestinal Stromal Tumor Drug sales, projected growth trends, production technology, application and end-user industry.
Gastrointestinal Stromal Tumor Drug Segment by Company
China Biopharmaceuticals
Zai Lab
CSPC Pharmaceuticals
Novartis
Mylan Pharms Inc.
Kelun Pharmaceuticals
CStone Pharmaceuticals
Hansoh Pharmaceuticals
Vannsh Life Sciences
Teva Pharmaceutical Industries Ltd.
Sun Pharmaceuticals
MSN Laboratories
Glenmark Pharmaceuticals Ltd.
Drug International
Dr. Reddy's Laboratories
Deciphera Pharmaceuticals
Bulat Pharmaceutical
Beacon Pharmaceuticals
Bayer Pharmaceuticals
Apotex Inc.
Actavis Generics
Gastrointestinal Stromal Tumor Drug Segment by Type
Ripretinib
Regorafenib
Sunitinib
Imatinib
Others
Gastrointestinal Stromal Tumor Drug Segment by Application
Hospital
Clinic
Others
Gastrointestinal Stromal Tumor Drug Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Colombia
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Gastrointestinal Stromal Tumor Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Gastrointestinal Stromal Tumor Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Gastrointestinal Stromal Tumor Drug.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Gastrointestinal Stromal Tumor Drug market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2020-2031).
Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Gastrointestinal Stromal Tumor Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Gastrointestinal Stromal Tumor Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Revenue of Gastrointestinal Stromal Tumor Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights of the report
Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.
According to APO Research, The global Gastrointestinal Stromal Tumor Drug market is projected to grow from US$ million in 2025 to US$ million by 2031, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.
The US & Canada market for Gastrointestinal Stromal Tumor Drug is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for Gastrointestinal Stromal Tumor Drug is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The China market for Gastrointestinal Stromal Tumor Drug is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Europe market for Gastrointestinal Stromal Tumor Drug is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global manufacturers of Gastrointestinal Stromal Tumor Drug include China Biopharmaceuticals, Zai Lab, CSPC Pharmaceuticals, Novartis, Mylan Pharms Inc., Kelun Pharmaceuticals, CStone Pharmaceuticals, Hansoh Pharmaceuticals and Vannsh Life Sciences, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
This report presents an overview of global market for Gastrointestinal Stromal Tumor Drug, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2020-2024, estimates for 2025, and projections of CAGR through 2031.
This report researches the key producers of Gastrointestinal Stromal Tumor Drug, also provides the sales of main regions and countries. Of the upcoming market potential for Gastrointestinal Stromal Tumor Drug, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Gastrointestinal Stromal Tumor Drug sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Gastrointestinal Stromal Tumor Drug market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for Gastrointestinal Stromal Tumor Drug sales, projected growth trends, production technology, application and end-user industry.
Gastrointestinal Stromal Tumor Drug Segment by Company
China Biopharmaceuticals
Zai Lab
CSPC Pharmaceuticals
Novartis
Mylan Pharms Inc.
Kelun Pharmaceuticals
CStone Pharmaceuticals
Hansoh Pharmaceuticals
Vannsh Life Sciences
Teva Pharmaceutical Industries Ltd.
Sun Pharmaceuticals
MSN Laboratories
Glenmark Pharmaceuticals Ltd.
Drug International
Dr. Reddy's Laboratories
Deciphera Pharmaceuticals
Bulat Pharmaceutical
Beacon Pharmaceuticals
Bayer Pharmaceuticals
Apotex Inc.
Actavis Generics
Gastrointestinal Stromal Tumor Drug Segment by Type
Ripretinib
Regorafenib
Sunitinib
Imatinib
Others
Gastrointestinal Stromal Tumor Drug Segment by Application
Hospital
Clinic
Others
Gastrointestinal Stromal Tumor Drug Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Colombia
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Gastrointestinal Stromal Tumor Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Gastrointestinal Stromal Tumor Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Gastrointestinal Stromal Tumor Drug.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Gastrointestinal Stromal Tumor Drug market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2020-2031).
Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Gastrointestinal Stromal Tumor Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Gastrointestinal Stromal Tumor Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Revenue of Gastrointestinal Stromal Tumor Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights of the report
Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.
Table of Contents
191 Pages
- 1 Market Overview
- 1.1 Product Definition
- 1.2 Global Gastrointestinal Stromal Tumor Drug Market Size, 2020 VS 2024 VS 2031
- 1.3 Global Gastrointestinal Stromal Tumor Drug Market Size Estimates and Forecasts (2020-2031)
- 1.4 Global Gastrointestinal Stromal Tumor Drug Sales Estimates and Forecasts (2020-2031)
- 1.5 Global Gastrointestinal Stromal Tumor Drug Market Average Price (2020-2031)
- 1.6 Assumptions and Limitations
- 1.7 Study Goals and Objectives
- 2 Global Gastrointestinal Stromal Tumor Drug Market Dynamics
- 2.1 Gastrointestinal Stromal Tumor Drug Industry Trends
- 2.2 Gastrointestinal Stromal Tumor Drug Industry Drivers
- 2.3 Gastrointestinal Stromal Tumor Drug Industry Opportunities and Challenges
- 2.4 Gastrointestinal Stromal Tumor Drug Industry Restraints
- 3 Gastrointestinal Stromal Tumor Drug Market by Manufacturers
- 3.1 Global Gastrointestinal Stromal Tumor Drug Revenue by Manufacturers (2020-2025)
- 3.2 Global Gastrointestinal Stromal Tumor Drug Sales by Manufacturers (2020-2025)
- 3.3 Global Gastrointestinal Stromal Tumor Drug Average Sales Price by Manufacturers (2020-2025)
- 3.4 Global Gastrointestinal Stromal Tumor Drug Industry Manufacturers Ranking, 2023 VS 2024 VS 2025
- 3.5 Global Gastrointestinal Stromal Tumor Drug Key Manufacturers Manufacturing Sites & Headquarters
- 3.6 Global Gastrointestinal Stromal Tumor Drug Manufacturers, Product Type & Application
- 3.7 Global Gastrointestinal Stromal Tumor Drug Manufacturers Establishment Date
- 3.8 Market Competitive Analysis
- 3.8.1 Global Gastrointestinal Stromal Tumor Drug Market CR5 and HHI
- 3.8.2 Global Top 5 and 10 Gastrointestinal Stromal Tumor Drug Players Market Share by Revenue in 2024
- 3.8.3 2024 Gastrointestinal Stromal Tumor Drug Tier 1, Tier 2, and Tier 3
- 4 Gastrointestinal Stromal Tumor Drug Market by Type
- 4.1 Gastrointestinal Stromal Tumor Drug Type Introduction
- 4.1.1 Ripretinib
- 4.1.2 Regorafenib
- 4.1.3 Sunitinib
- 4.1.4 Imatinib
- 4.1.5 Others
- 4.2 Global Gastrointestinal Stromal Tumor Drug Sales by Type
- 4.2.1 Global Gastrointestinal Stromal Tumor Drug Sales by Type (2020 VS 2024 VS 2031)
- 4.2.2 Global Gastrointestinal Stromal Tumor Drug Sales by Type (2020-2031)
- 4.2.3 Global Gastrointestinal Stromal Tumor Drug Sales Market Share by Type (2020-2031)
- 4.3 Global Gastrointestinal Stromal Tumor Drug Revenue by Type
- 4.3.1 Global Gastrointestinal Stromal Tumor Drug Revenue by Type (2020 VS 2024 VS 2031)
- 4.3.2 Global Gastrointestinal Stromal Tumor Drug Revenue by Type (2020-2031)
- 4.3.3 Global Gastrointestinal Stromal Tumor Drug Revenue Market Share by Type (2020-2031)
- 5 Gastrointestinal Stromal Tumor Drug Market by Application
- 5.1 Gastrointestinal Stromal Tumor Drug Application Introduction
- 5.1.1 Hospital
- 5.1.2 Clinic
- 5.1.3 Others
- 5.2 Global Gastrointestinal Stromal Tumor Drug Sales by Application
- 5.2.1 Global Gastrointestinal Stromal Tumor Drug Sales by Application (2020 VS 2024 VS 2031)
- 5.2.2 Global Gastrointestinal Stromal Tumor Drug Sales by Application (2020-2031)
- 5.2.3 Global Gastrointestinal Stromal Tumor Drug Sales Market Share by Application (2020-2031)
- 5.3 Global Gastrointestinal Stromal Tumor Drug Revenue by Application
- 5.3.1 Global Gastrointestinal Stromal Tumor Drug Revenue by Application (2020 VS 2024 VS 2031)
- 5.3.2 Global Gastrointestinal Stromal Tumor Drug Revenue by Application (2020-2031)
- 5.3.3 Global Gastrointestinal Stromal Tumor Drug Revenue Market Share by Application (2020-2031)
- 6 Global Gastrointestinal Stromal Tumor Drug Sales by Region
- 6.1 Global Gastrointestinal Stromal Tumor Drug Sales by Region: 2020 VS 2024 VS 2031
- 6.2 Global Gastrointestinal Stromal Tumor Drug Sales by Region (2020-2031)
- 6.2.1 Global Gastrointestinal Stromal Tumor Drug Sales by Region (2020-2025)
- 6.2.2 Global Gastrointestinal Stromal Tumor Drug Sales Forecasted by Region (2025-2030)
- 6.3 North America
- 6.3.1 North America Gastrointestinal Stromal Tumor Drug Sales Growth Rate by Country: 2020 VS 2024 VS 2031
- 6.3.2 North America Gastrointestinal Stromal Tumor Drug Sales by Country (2020-2031)
- 6.3.3 U.S.
- 6.3.4 Canada
- 6.3.5 Mexico
- 6.4 Europe
- 6.4.1 Europe Gastrointestinal Stromal Tumor Drug Sales Growth Rate by Country: 2020 VS 2024 VS 2031
- 6.4.2 Europe Gastrointestinal Stromal Tumor Drug Sales by Country (2020-2031)
- 6.4.3 Germany
- 6.4.4 France
- 6.4.5 U.K.
- 6.4.6 Italy
- 6.4.7 Netherlands
- 6.5 Asia Pacific
- 6.5.1 Asia Pacific Gastrointestinal Stromal Tumor Drug Sales Growth Rate by Country: 2020 VS 2024 VS 2031
- 6.5.2 Asia Pacific Gastrointestinal Stromal Tumor Drug Sales by Country (2020-2031)
- 6.5.3 China
- 6.5.4 Japan
- 6.5.5 South Korea
- 6.5.6 Southeast Asia
- 6.5.7 India
- 6.5.8 Australia
- 6.6 South America, Middle East and Africa
- 6.6.1 South America, Middle East and Africa Gastrointestinal Stromal Tumor Drug Sales Growth Rate by Country: 2020 VS 2024 VS 2031
- 6.6.2 South America, Middle East and Africa Gastrointestinal Stromal Tumor Drug Sales by Country (2020-2031)
- 6.6.3 Brazil
- 6.6.4 South Africa
- 6.6.5 Saudi Arabia
- 6.6.6 Turkey
- 6.6.6 Argentina
- 6.6.6 UAE
- 6.6.6 Egypt
- 6.6.6 Chile
- 7 Global Gastrointestinal Stromal Tumor Drug Revenue by Region
- 7.1 Global Gastrointestinal Stromal Tumor Drug Revenue by Region
- 7.1.1 Global Gastrointestinal Stromal Tumor Drug Revenue by Region: 2020 VS 2024 VS 2031
- 7.1.2 Global Gastrointestinal Stromal Tumor Drug Revenue by Region (2020-2025)
- 7.1.3 Global Gastrointestinal Stromal Tumor Drug Revenue by Region (2026-2031)
- 7.1.4 Global Gastrointestinal Stromal Tumor Drug Revenue Market Share by Region (2020-2031)
- 7.2 North America
- 7.2.1 North America Gastrointestinal Stromal Tumor Drug Revenue (2020-2031)
- 7.2.2 North America Gastrointestinal Stromal Tumor Drug Revenue Share by Country: 2020 VS 2024 VS 2031
- 7.3 Europe
- 7.3.1 Europe Gastrointestinal Stromal Tumor Drug Revenue (2020-2031)
- 7.3.2 Europe Gastrointestinal Stromal Tumor Drug Revenue Share by Country: 2020 VS 2024 VS 2031
- 7.4 Asia-Pacific
- 7.4.1 Asia-Pacific Gastrointestinal Stromal Tumor Drug Revenue (2020-2031)
- 7.4.2 Asia-Pacific Gastrointestinal Stromal Tumor Drug Revenue Share by Country: 2020 VS 2024 VS 2031
- 7.5 South America, Middle East and Africa
- 7.5.1 South America, Middle East and Africa Gastrointestinal Stromal Tumor Drug Revenue (2020-2031)
- 7.5.2 South America, Middle East and Africa Gastrointestinal Stromal Tumor Drug Revenue Share by Country: 2020 VS 2024 VS 2031
- 8 Company Profiles
- 8.1 China Biopharmaceuticals
- 8.1.1 China Biopharmaceuticals Comapny Information
- 8.1.2 China Biopharmaceuticals Business Overview
- 8.1.3 China Biopharmaceuticals Gastrointestinal Stromal Tumor Drug Sales, Price, Revenue and Gross Margin (2020-2025)
- 8.1.4 China Biopharmaceuticals Gastrointestinal Stromal Tumor Drug Product Portfolio
- 8.1.5 China Biopharmaceuticals Recent Developments
- 8.2 Zai Lab
- 8.2.1 Zai Lab Comapny Information
- 8.2.2 Zai Lab Business Overview
- 8.2.3 Zai Lab Gastrointestinal Stromal Tumor Drug Sales, Price, Revenue and Gross Margin (2020-2025)
- 8.2.4 Zai Lab Gastrointestinal Stromal Tumor Drug Product Portfolio
- 8.2.5 Zai Lab Recent Developments
- 8.3 CSPC Pharmaceuticals
- 8.3.1 CSPC Pharmaceuticals Comapny Information
- 8.3.2 CSPC Pharmaceuticals Business Overview
- 8.3.3 CSPC Pharmaceuticals Gastrointestinal Stromal Tumor Drug Sales, Price, Revenue and Gross Margin (2020-2025)
- 8.3.4 CSPC Pharmaceuticals Gastrointestinal Stromal Tumor Drug Product Portfolio
- 8.3.5 CSPC Pharmaceuticals Recent Developments
- 8.4 Novartis
- 8.4.1 Novartis Comapny Information
- 8.4.2 Novartis Business Overview
- 8.4.3 Novartis Gastrointestinal Stromal Tumor Drug Sales, Price, Revenue and Gross Margin (2020-2025)
- 8.4.4 Novartis Gastrointestinal Stromal Tumor Drug Product Portfolio
- 8.4.5 Novartis Recent Developments
- 8.5 Mylan Pharms Inc.
- 8.5.1 Mylan Pharms Inc. Comapny Information
- 8.5.2 Mylan Pharms Inc. Business Overview
- 8.5.3 Mylan Pharms Inc. Gastrointestinal Stromal Tumor Drug Sales, Price, Revenue and Gross Margin (2020-2025)
- 8.5.4 Mylan Pharms Inc. Gastrointestinal Stromal Tumor Drug Product Portfolio
- 8.5.5 Mylan Pharms Inc. Recent Developments
- 8.6 Kelun Pharmaceuticals
- 8.6.1 Kelun Pharmaceuticals Comapny Information
- 8.6.2 Kelun Pharmaceuticals Business Overview
- 8.6.3 Kelun Pharmaceuticals Gastrointestinal Stromal Tumor Drug Sales, Price, Revenue and Gross Margin (2020-2025)
- 8.6.4 Kelun Pharmaceuticals Gastrointestinal Stromal Tumor Drug Product Portfolio
- 8.6.5 Kelun Pharmaceuticals Recent Developments
- 8.7 CStone Pharmaceuticals
- 8.7.1 CStone Pharmaceuticals Comapny Information
- 8.7.2 CStone Pharmaceuticals Business Overview
- 8.7.3 CStone Pharmaceuticals Gastrointestinal Stromal Tumor Drug Sales, Price, Revenue and Gross Margin (2020-2025)
- 8.7.4 CStone Pharmaceuticals Gastrointestinal Stromal Tumor Drug Product Portfolio
- 8.7.5 CStone Pharmaceuticals Recent Developments
- 8.8 Hansoh Pharmaceuticals
- 8.8.1 Hansoh Pharmaceuticals Comapny Information
- 8.8.2 Hansoh Pharmaceuticals Business Overview
- 8.8.3 Hansoh Pharmaceuticals Gastrointestinal Stromal Tumor Drug Sales, Price, Revenue and Gross Margin (2020-2025)
- 8.8.4 Hansoh Pharmaceuticals Gastrointestinal Stromal Tumor Drug Product Portfolio
- 8.8.5 Hansoh Pharmaceuticals Recent Developments
- 8.9 Vannsh Life Sciences
- 8.9.1 Vannsh Life Sciences Comapny Information
- 8.9.2 Vannsh Life Sciences Business Overview
- 8.9.3 Vannsh Life Sciences Gastrointestinal Stromal Tumor Drug Sales, Price, Revenue and Gross Margin (2020-2025)
- 8.9.4 Vannsh Life Sciences Gastrointestinal Stromal Tumor Drug Product Portfolio
- 8.9.5 Vannsh Life Sciences Recent Developments
- 8.10 Teva Pharmaceutical Industries Ltd.
- 8.10.1 Teva Pharmaceutical Industries Ltd. Comapny Information
- 8.10.2 Teva Pharmaceutical Industries Ltd. Business Overview
- 8.10.3 Teva Pharmaceutical Industries Ltd. Gastrointestinal Stromal Tumor Drug Sales, Price, Revenue and Gross Margin (2020-2025)
- 8.10.4 Teva Pharmaceutical Industries Ltd. Gastrointestinal Stromal Tumor Drug Product Portfolio
- 8.10.5 Teva Pharmaceutical Industries Ltd. Recent Developments
- 8.11 Sun Pharmaceuticals
- 8.11.1 Sun Pharmaceuticals Comapny Information
- 8.11.2 Sun Pharmaceuticals Business Overview
- 8.11.3 Sun Pharmaceuticals Gastrointestinal Stromal Tumor Drug Sales, Price, Revenue and Gross Margin (2020-2025)
- 8.11.4 Sun Pharmaceuticals Gastrointestinal Stromal Tumor Drug Product Portfolio
- 8.11.5 Sun Pharmaceuticals Recent Developments
- 8.12 MSN Laboratories
- 8.12.1 MSN Laboratories Comapny Information
- 8.12.2 MSN Laboratories Business Overview
- 8.12.3 MSN Laboratories Gastrointestinal Stromal Tumor Drug Sales, Price, Revenue and Gross Margin (2020-2025)
- 8.12.4 MSN Laboratories Gastrointestinal Stromal Tumor Drug Product Portfolio
- 8.12.5 MSN Laboratories Recent Developments
- 8.13 Glenmark Pharmaceuticals Ltd.
- 8.13.1 Glenmark Pharmaceuticals Ltd. Comapny Information
- 8.13.2 Glenmark Pharmaceuticals Ltd. Business Overview
- 8.13.3 Glenmark Pharmaceuticals Ltd. Gastrointestinal Stromal Tumor Drug Sales, Price, Revenue and Gross Margin (2020-2025)
- 8.13.4 Glenmark Pharmaceuticals Ltd. Gastrointestinal Stromal Tumor Drug Product Portfolio
- 8.13.5 Glenmark Pharmaceuticals Ltd. Recent Developments
- 8.14 Drug International
- 8.14.1 Drug International Comapny Information
- 8.14.2 Drug International Business Overview
- 8.14.3 Drug International Gastrointestinal Stromal Tumor Drug Sales, Price, Revenue and Gross Margin (2020-2025)
- 8.14.4 Drug International Gastrointestinal Stromal Tumor Drug Product Portfolio
- 8.14.5 Drug International Recent Developments
- 8.15 Dr. Reddy's Laboratories
- 8.15.1 Dr. Reddy's Laboratories Comapny Information
- 8.15.2 Dr. Reddy's Laboratories Business Overview
- 8.15.3 Dr. Reddy's Laboratories Gastrointestinal Stromal Tumor Drug Sales, Price, Revenue and Gross Margin (2020-2025)
- 8.15.4 Dr. Reddy's Laboratories Gastrointestinal Stromal Tumor Drug Product Portfolio
- 8.15.5 Dr. Reddy's Laboratories Recent Developments
- 8.16 Deciphera Pharmaceuticals
- 8.16.1 Deciphera Pharmaceuticals Comapny Information
- 8.16.2 Deciphera Pharmaceuticals Business Overview
- 8.16.3 Deciphera Pharmaceuticals Gastrointestinal Stromal Tumor Drug Sales, Price, Revenue and Gross Margin (2020-2025)
- 8.16.4 Deciphera Pharmaceuticals Gastrointestinal Stromal Tumor Drug Product Portfolio
- 8.16.5 Deciphera Pharmaceuticals Recent Developments
- 8.17 Bulat Pharmaceutical
- 8.17.1 Bulat Pharmaceutical Comapny Information
- 8.17.2 Bulat Pharmaceutical Business Overview
- 8.17.3 Bulat Pharmaceutical Gastrointestinal Stromal Tumor Drug Sales, Price, Revenue and Gross Margin (2020-2025)
- 8.17.4 Bulat Pharmaceutical Gastrointestinal Stromal Tumor Drug Product Portfolio
- 8.17.5 Bulat Pharmaceutical Recent Developments
- 8.18 Beacon Pharmaceuticals
- 8.18.1 Beacon Pharmaceuticals Comapny Information
- 8.18.2 Beacon Pharmaceuticals Business Overview
- 8.18.3 Beacon Pharmaceuticals Gastrointestinal Stromal Tumor Drug Sales, Price, Revenue and Gross Margin (2020-2025)
- 8.18.4 Beacon Pharmaceuticals Gastrointestinal Stromal Tumor Drug Product Portfolio
- 8.18.5 Beacon Pharmaceuticals Recent Developments
- 8.19 Bayer Pharmaceuticals
- 8.19.1 Bayer Pharmaceuticals Comapny Information
- 8.19.2 Bayer Pharmaceuticals Business Overview
- 8.19.3 Bayer Pharmaceuticals Gastrointestinal Stromal Tumor Drug Sales, Price, Revenue and Gross Margin (2020-2025)
- 8.19.4 Bayer Pharmaceuticals Gastrointestinal Stromal Tumor Drug Product Portfolio
- 8.19.5 Bayer Pharmaceuticals Recent Developments
- 8.20 Apotex Inc.
- 8.20.1 Apotex Inc. Comapny Information
- 8.20.2 Apotex Inc. Business Overview
- 8.20.3 Apotex Inc. Gastrointestinal Stromal Tumor Drug Sales, Price, Revenue and Gross Margin (2020-2025)
- 8.20.4 Apotex Inc. Gastrointestinal Stromal Tumor Drug Product Portfolio
- 8.20.5 Apotex Inc. Recent Developments
- 8.21 Actavis Generics
- 8.21.1 Actavis Generics Comapny Information
- 8.21.2 Actavis Generics Business Overview
- 8.21.3 Actavis Generics Gastrointestinal Stromal Tumor Drug Sales, Price, Revenue and Gross Margin (2020-2025)
- 8.21.4 Actavis Generics Gastrointestinal Stromal Tumor Drug Product Portfolio
- 8.21.5 Actavis Generics Recent Developments
- 9 Value Chain and Sales Channels Analysis
- 9.1 Gastrointestinal Stromal Tumor Drug Value Chain Analysis
- 9.1.1 Gastrointestinal Stromal Tumor Drug Key Raw Materials
- 9.1.2 Raw Materials Key Suppliers
- 9.1.3 Manufacturing Cost Structure
- 9.1.4 Gastrointestinal Stromal Tumor Drug Production Mode & Process
- 9.2 Gastrointestinal Stromal Tumor Drug Sales Channels Analysis
- 9.2.1 Direct Comparison with Distribution Share
- 9.2.2 Gastrointestinal Stromal Tumor Drug Distributors
- 9.2.3 Gastrointestinal Stromal Tumor Drug Customers
- 10 Concluding Insights
- 11 Appendix
- 11.1 Reasons for Doing This Study
- 11.2 Research Methodology
- 11.3 Research Process
- 11.4 Authors List of This Report
- 11.5 Data Source
- 11.5.1 Secondary Sources
- 11.5.2 Primary Sources
- 11.6 Disclaimer
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.